Sunshine Biopharma Says After Conclusion Of Internal Review Of Lab Results, Gave Notice To Jewish General Hospital Of Termination Of Research Agreement; Now Paused IND-Enabling Studies Of Adva-27a Effective On December 2, 2023
Portfolio Pulse from Benzinga Newsdesk
Sunshine Biopharma has terminated its research agreement with Jewish General Hospital following unfavorable lab results on testing of its anti-cancer drug, Adva-27a. The company has paused the IND-enabling studies of Adva-27a pending a review of the possibility of chemical modification of the compound.
November 02, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sunshine Biopharma's termination of its research agreement with Jewish General Hospital and pausing of IND-enabling studies of Adva-27a could potentially impact the company's stock negatively in the short term.
The termination of the research agreement and pausing of studies due to unfavorable lab results could be seen as a setback for Sunshine Biopharma, potentially leading to a decrease in investor confidence and a negative impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100